Jim Simons
CRVS icon

Jim Simons’s Corvus Pharmaceuticals CRVS Stock Holding History

Jim Simons’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Buy
+81,310
New +$1.3M ﹤0.01% 2171
2025
Q3 		– Sell
-165,188
Closed -$661K – 3570
2025
Q2 		$661K Sell
165,188
-99,800
-38% -$363K ﹤0.01% 2697
2025
Q1 		$843K Sell
264,988
-125,700
-32% -$592K ﹤0.01% 2515
2024
Q4 		$2.09M Buy
390,688
+4,100
+1% +$30.6K ﹤0.01% 2022
2024
Q3 		$2.04M Sell
386,588
-177,344
-31% -$637K ﹤0.01% 2007
2024
Q2 		$1.03M Sell
563,932
-73,100
-11% -$136K ﹤0.01% 2300
2024
Q1 		$1.13M Buy
637,032
+49,600
+8% +$104K ﹤0.01% 2408
2023
Q4 		$1.03M Buy
587,432
+165,689
+39% +$242K ﹤0.01% 2381
2023
Q3 		$616K Sell
421,743
-67,930
-14% -$144K ﹤0.01% 2624
2023
Q2 		$1.12M Sell
489,673
-16,359
-3% -$34K ﹤0.01% 2399
2023
Q1 		$460K Sell
506,032
-142,600
-22% -$111K ﹤0.01% 2927
2022
Q4 		$551K Sell
648,632
-326,887
-34% -$289K ﹤0.01% 2902
2022
Q3 		$798K Buy
975,519
+12,587
+1% +$12K ﹤0.01% 2633
2022
Q2 		$953K Buy
962,932
+61,800
+7% +$75.8K ﹤0.01% 2755
2022
Q1 		$1.48M Sell
901,132
-142,600
-14% -$261K ﹤0.01% 2448
2021
Q4 		$2.52M Buy
1,043,732
+429,362
+70% +$1.67M ﹤0.01% 1969
2021
Q3 		$2.97M Sell
614,370
-43,700
-7% -$129K ﹤0.01% 1790
2021
Q2 		$1.76M Sell
658,070
-5,400
-0.8% -$14.9K ﹤0.01% 2342
2021
Q1 		$2.04M Sell
663,470
-133,600
-17% -$483K ﹤0.01% 2211
2020
Q4 		$2.84M Sell
797,070
-77,930
-9% -$314K ﹤0.01% 1923
2020
Q3 		$3.51M Sell
875,000
-156,900
-15% -$627K ﹤0.01% 1780
2020
Q2 		$2.81M Buy
1,031,900
+101,200
+11% +$299K ﹤0.01% 1980
2020
Q1 		$1.96M Buy
930,700
+24,500
+3% +$99.5K ﹤0.01% 2058
2019
Q4 		$4.93M Buy
906,200
+54,422
+6% +$190K ﹤0.01% 1863
2019
Q3 		$2.56M Buy
851,778
+18,680
+2% +$78.4K ﹤0.01% 2149
2019
Q2 		$3.12M Buy
833,098
+51,398
+7% +$201K ﹤0.01% 2100
2019
Q1 		$3.14M Buy
781,700
+119,400
+18% +$504K ﹤0.01% 2085
2018
Q4 		$2.43M Buy
662,300
+265,400
+67% +$1.81M ﹤0.01% 2125
2018
Q3 		$3.4M Buy
396,900
+72,000
+22% +$720K ﹤0.01% 2020
2018
Q2 		$3.57M Sell
324,900
-101,800
-24% -$1.14M ﹤0.01% 1972
2018
Q1 		$4.92M Buy
426,700
+192,500
+82% +$1.82M 0.01% 1820
2017
Q4 		$2.43M Buy
234,200
+39,900
+21% +$511K ﹤0.01% 2230
2017
Q3 		$3.1M Buy
194,300
+57,200
+42% +$791K ﹤0.01% 2057
2017
Q2 		$1.66M Buy
137,100
+79,300
+137% +$847K ﹤0.01% 2344
2017
Q1 		$1.2M Buy
+57,800
New +$905K ﹤0.01% 2474

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jim Simons's CRVS Position: Q1 2026 in Review

Jim Simons opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 81,310 shares worth $1.19M. The stake represents ﹤0.01% of the portfolio and ranks #2171 among its holdings. This is a return to the name: Jim Simons previously reported a position in CRVS as recently as Q2 2025.

Jim Simons first reported a position in CRVS in Q1 2017 and has held it in 35 quarters since. The position peaked at $4.93M in Q4 2019. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Jim Simons held 81,310 shares of Corvus Pharmaceuticals worth $1.19M as of Q1 2026.
  • Corvus Pharmaceuticals was a new Jim Simons position in Q1 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2171 holding.
  • Jim Simons first reported a position in Corvus Pharmaceuticals in Q1 2017 and has held it in 35 quarters since.
  • Jim Simons's Corvus Pharmaceuticals position peaked at $4.93M in Q4 2019.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.